Connect with us

Politics

Connecticut Lawmakers Delay Marijuana Legalization Vote To Special Session

Published

on

With just hours left to go in Connecticut’s regular legislative session, House lawmakers on Wednesday decided to delay a planned vote on legalizing marijuana in the state. The proposal, which narrowly passed the Senate on Tuesday, will be taken up again during a special session by the end of the month.

Earlier in the day, House Speaker Matt Ritter (D) had said the chamber could still take up the legislation before the midnight deadline on the current session, but left open the possibility it might not happen.

“We will be voting in the next week on that bill,” he said during a press briefing Wednesday morning. “Could be today, could be tomorrow, could be Friday, could be Saturday, could be Sunday—we will be getting that bill passed.”

Democratic leaders have insisted they have the votes to push through the nearly 300-page cannabis bill introduced over the weekend, but Republicans have broadly opposed it. Many expected a drawn-out debate Wednesday night, with GOP representatives trying to run out the clock to prevent a vote.

“It’s one thing to have an honest, robust debate on a complicated topic,” Ritter said. “The concern of my caucus is, is it four or five people that never want to stop?”

By mid-afternoon, Ritter had announced that the bill wouldn’t be called at all on Wednesday. Instead, legalization will be taken up again during a special legislative session, which is not yet scheduled but will take place before the fiscal year ends on June 30. The current bill will technically die at midnight on Wednesday, meaning a new legislative vehicle will have to clear both chambers during the special session.

House Majority Leader Jason Rojas (D) will be coordinating any changes to the bill between now and then, Ritter said.

At Monday’s briefing, Rojas said he’s open to working with Republicans but is unlikely to amend the bill itself.

“I know they’re concerned about how late the bill came out. I guess I would share my concern about how late they chose to come to the table,” he said. “I’m still willing to listen and consider some of the changes they might make. I don’t know that we would amend the bill necessarily, but we’d find another vehicle to potentially accommodate some of the requests.”

Groups in favor of cannabis legalization downplayed the delay. DeVaughn Ward, senior legislative counsel for Marijuana Policy Project, told Marijuana Moment that the group is “encouraged that legislative leadership is committed to getting the bill done.”

“While we’d hoped the bill would be past the finish line during the regular session, voting a few days later will in no way delay legalization,” he said. “Legal possession will start on July 1 whether the bill passes today or a little later.”

Ward also noted that, if the policy change is adopted, Connecticut would be the third state to pass legalization during a special session this year, after New Mexico and Virginia. “We’re glad legislatures are recognizing that this long overdue reform is worth working overtime to get done and get done right,” he said.

The current bill, Senate Bill 1118, is the product of weeks of negotiations between legislative leaders and Gov. Ned Lamont’s (D) office. It incorporates elements of Lamont’s own proposal, SB 888, as well as an equity-focused legalization bill, HB 6377, from Rep. Robyn Porter (D).

As passed by the Senate, the legislation would legalize personal possession and use of cannabis by adults 21 and older and eventually launch a regulated commercial cannabis market in Connecticut, licensing growers, retailers, manufacturers and delivery services. The Department of Consumer Protection (DCP) would be in charge of licensing and regulating cannabis businesses, with legal sales expected to begin in mid-2022.

Half of all business licenses would need to be issued to social equity applicants, defined as people who have lived in geographic areas disproportionately impacted by the war on drugs and who make no more than three times the state’s median income. Those applicants could also qualify for technical assistance, workforce training and funding to cover startup costs. Much of the revenue from the new commercial market would be reinvested back into communities hit hardest by the drug war.

For those who don’t want to buy cannabis commercially, home cultivation would also be allowed under the bill—first for medical patients, then eventually for all adults 21 and older.

Here are some key details about the Senate-approved legislation:

  • It would allow adults 21 and older to possess up to 1.5 ounces of cannabis starting on July 1, and it would establish a retail market, with Rojas anticipating sales to launch in May 2022.
  • Regulators with the Department of Consumer Protection (DCP) would be responsible for issuing licenses for growers, retailers, manufacturers and delivery services.
  • Social equity applicants—defined as people who have lived in geographic areas disproportionately impacted by the war on drugs and who make no more than three times the state’s median income—would be entitled to half of those licenses.
  • A significant amount of tax revenue from cannabis sales would go toward community reinvestment.
  • Home cultivation would be permitted—first to medical marijuana patients and then later to adult-use consumers.
  • Criminal convictions for possession of less than four ounces of cannabis would be automatically expunged beginning in 2023. Expungement would apply to possession convictions from January 1, 2000 through September 15, 2015.
  • Beginning July 1, 2022, individuals could petition to have other cannabis convictions erased, such as for possession of marijuana paraphernalia or the sale of small amounts of cannabis.
  • The smell of cannabis alone would no longer be a legal basis for law enforcement to stop and search individuals, nor would suspected possession of up to five ounces of marijuana.
  • Absent federal restrictions, employers would not be able to take adverse actions against workers merely for testing positive for cannabis metabolites.
  • Rental tenants, students at institutions of higher learning, and professionals in licensed occupations would be protected from certain types of discrimination around legal cannabis use. People who test positive for cannabis metabolites, which suggest past use, could not be denied organ transplants or other medical care, educational opportunities or have action taken against them by the Department of Children and Families without another evidence-based reason for the action.
  • Cannabis-related advertising could not target people under 21, and businesses that allow minors on their premises would be penalized. Licensees who sell to minors would be guilty of a Class A misdemeanor, punishable by up to a year in prison and a $2,000 fine. People in charge of households or private properties who allow minors to possess cannabis there would also face a Class A misdemeanor.
  • Adults 18 to 20 years old who are caught with small amounts cannabis would be subject to a $50 civil fine, although subsequent violations could carry a $150 fine and mandatory community service. All possession offenses would require individuals to sign a statement acknowledging the health risks of cannabis to young people.
  • Minors under 18 could not be arrested for cannabis possession. A first offense would carry a written warning and possible referral to youth services, while a third or subsequent offense, or possession of more than five ounces of marijuana, would send the individual to juvenile court.
    Local governments could prohibit cannabis businesses or ban cannabis delivery within their jurisdictions. Municipalities could also set reasonable limits on the number of licensed businesses, their locations, operating hours and signage.
  • Until June 30, 2024, the number of licensed cannabis retailers could not exceed one per 25,000 residents. After that, state regulators will set a new maximum.
  • Cannabis products would be capped at 30 percent THC by weight for cannabis flower and all other products except pre-filled vape cartridges at 60 percent THC, though those limits could be further adjusted by regulators. Retailers would also need to provide access to low-THC and high-CBD products. Products designed to appeal to children would be forbidden.
  • The state’s general sales tax of 6.35 percent would apply to cannabis, and an additional excise tax based on THC content would be imposed. The bill also authorizes a 3 percent municipal tax, which must be used for community reinvestment.
  • Until June 30, 2023, all excise tax would flow to the state’s general fund. For three years after that, 60 percent of the tax revenue will go to a new Social Equity and Innovation Fund. That amount would increase to 65 percent in 2026 and 75 percent in 2028. Other revenue would go to the state’s general fund as well as prevention and recovery services around drug use disorders.
  • Existing medical marijuana dispensaries could become “hybrid retailers” to also serve adult-use consumers. Regulators would begin accepting applications for hybrid permits in September 2021, and applicants would need to submit a conversion plan and pay a $1 million fee. That fee could be cut in half if they create a so-called equity joint venture, which would need to be majority owned by a social equity applicant. Medical marijuana growers could also begin cultivating adult-use cannabis in the second half this year, though they would need to pay a fee of up to $3 million.
  • Licensing fees for social equity applicants would be 50 percent of open licensing fees. Applicants would need to pay a small fee to enter a lottery, then a larger fee if they’re granted a license. Social equity licensees would also receive a 50 percent discount on license fees for the first three years of renewals.
  • The state would be allowed to enter into cannabis-related agreements with tribal governments, such as the Mashantucket Pequot Tribe and the Mohegan Tribe of Indians.

The Senate adopted one amendment to the bill before passing it on Tuesday that makes a number of substantial and technical changes. Among other revisions, it deletes a section that would have allowed backers of marijuana producers to obtain cultivation licenses without being subject to a lottery and clarifies that a higher percentage of equity joint-venture owners be from disproportionately impacted areas. It also expands equity provisions of the bill so that 100 percent of profits with joint ventures with existing businesses go to equity partners, rather than the 5 percent in the original bill, and exempts medical marijuana from potency limits that apply to adult-use products.

A fiscal note on bill projects that taxes and fees for marijuana would bring in an estimated $4.1 million in additional revenue for the state and municipalities in fiscal year 2022, which would grow over time to a projected annual haul of $73.4 million by fiscal year 2026.

Republicans, however, have warned that legalization would cause problems for law enforcement, create public health hazards and risk normalizing youth cannabis use. GOP lawmakers in the House, including Rep. Vincent Candelora, have also criticized the bill after noticing a provision, since removed, that would allow a grower to bypass the state’s lottery licensing system.

Republicans have also blasted what they’ve said are severe public health risks from legalization. “We’re legitimizing a highly potent, mind-altering drug to collect our little piece of gold that we may get from it,” Sen. Heather Somers (R) said Monday on the Senate floor. “This bill may generate $80 million in revenue, but the costs will well outstrip any kind of revenue we’ll see come in.”


Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

If a legalization measure isn’t enacted this year, Lamont said last month that the issue could ultimately go before voters.

“Marijuana is sort of interesting to me. When it goes to a vote of the people through some sort of a referendum, it passes overwhelmingly. When it goes through a legislature and a lot of telephone calls are made, it’s slim or doesn’t pass,” the governor said. “We’re trying to do it through the legislature. Folks are elected to make a decision, and we’ll see where it goes. If it doesn’t, we’ll probably end up in a referendum.”

Ritter said late last month that he feels there’s a 57-43 chance that the legislation is approved, whereas he previously gave it a 50-50 chance.

He last year that if the legislature isn’t able to pass a legalization bill, he will move to put a question on the state’s 2022 ballot that would leave the matter to voters.

According to recent polling, if legalization did go before voters, it would pass.

Sixty-four percent of residents in the state favor legalizing cannabis for adult use, according to a survey from Sacred Heart University that was released last week.

The competing legalization measure from Rep. Robyn Porter (D), which is favored by many legalization advocates for its focus on social equity, was approved in the Labor and Public Employees Committee in March.

Lamont, who convened an informal work group in recent months to make recommendations on the policy change, initially described his legalization plan as a “comprehensive framework for the cultivation, manufacture, sale, possession, use, and taxation of cannabis that prioritizes public health, public safety, and social justice.”

But while advocates have strongly criticized the governor’s plan as inadequate when it comes to equity provisions, Ritter said in March that “optimism abounds” as lawmakers work to merge proposals into a final legalization bill.

Rojas also said that “in principle, equity is important to both the administration and the legislature, and we’re going to work through those details.”

To that end, the majority leader said that working groups have been formed in the Democratic caucuses of the legislature to go through the governor’s proposal and the committee-approved reform bill.

In February, a Lamont administration official stressed during a hearing in the House Judiciary Committee that Lamont’s proposal it is “not a final bill,” and they want activists “at the table” to further inform the legislation.

The legislature has considered legalization proposals on several occasions in recent years, including a bill that Democrats introduced last year on the governor’s behalf. Those bills stalled, however.

Lamont reiterated his support for legalizing marijuana during his annual State of the State address in January, stating that he would be working with the legislature to advance the reform this session.

The governor has compared the need for regional coordination on marijuana policy to the coronavirus response, stating that officials have “got to think regionally when it comes to how we deal with the pandemic—and I think we have to think regionally when it comes to marijuana, as well.”

He also said that legalization in Connecticut could potentially reduce the spread of COVID-19 by limiting out-of-state trips to purchase legal cannabis in neighboring states such as Massachusetts and New Jersey.

Connecticut Governor Signs Psychedelics Study Measure As He Awaits Marijuana Legalization Bill

Photo courtesy of Philip Steffan

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.

Ben Adlin is a Seattle-based writer and editor. He has covered cannabis as a journalist since 2011, most recently as a senior news editor for Leafly.

Politics

Congress To Vote On Marijuana, Psychedelics And CBD Amendments This Week Following Committee Action

Published

on

A key House committee on Monday cleared a series of cannabis and psychedelics-related amendments for floor votes as part of large-scale spending legislation. That floor action could happen as soon as Tuesday.

However, the panel also blocked two measures on housing protections for cannabis consumers that legalization supporters hoped to see advance.

One of the most notable amendments the House Rules Committee allowed to move forward for possible attachment to appropriations legislation would remove a rider that advocates say has restricted federal funds for research into Schedule I drugs, including psychedelics such as psilocybin, MDMA and ibogaine.

The reform measure is being sponsored by Rep. Alexandria Ocasio-Cortez (D-NY), and it targets 1990s-era provision that’s long been part of spending legislation for the Department of Health and Human Services (HHS). The congresswoman attempted to eliminate the language via an amendment in 2019 only to have it defeated by Republicans as well as a majority of her party. But it’s far from the only measure being proposed this appropriations season when it comes to drug policy matters.

Some are being backed by reform advocates, while others have received sharp criticism.

One pro-reform amendment that’s advancing would encourage the Food and Drug Administration (FDA) to approve rules allowing CBD as a dietary supplement and food ingredient.

On the other side, there is a proposal from Rep. Debbie Lesko (R-AZ) to the HHS appropriations bill to eliminate a rider that’s currently in the bill that “allows federal funding to go to institutions of higher education that are conducting research on marijuana.”

The reason this measure has generated particular pushback is because research into cannabis is an overwhelmingly bipartisan issue, and top federal drug officials have repeatedly urged Congress to support policies that make it easier to study the risks and benefits of the plant. What’s more, Lesko represents a state with adult-use legalization on the books.

Activists are disappointed that two marijuana reform measures from Rep. Eleanor Holmes Norton (D-DC) are being blocked from floor consideration. Her proposals—which were aimed at appropriations legislation for the Department of Housing and Urban Development (HUD)—would have made it so marijuana possession or consumption could not be used as the sole basis for denying people access to public housing. One Norton amendment was narrowly focused on medical cannabis while a second measure would have covered all marijuana use that’s legal under state laws.

“It’s disappointing that those who rely on public support for housing will continue to be discriminated against for their state-legal choices,” NORML Political Director Justin Strekal told Marijuana Moment.

Advocates were surprised that the Rules Committee, chaired by marijuana reform supporter Rep. James McGovern (D-MA), sought to prevent a floor vote on the Norton cannabis amendments.

A committee spokesperson told Marijuana Moment that the proposals “had points of order against them and we never make amendments in order with points of order against them.”

Here are the descriptions of measures that the Rules Committee made in order for floor votes: 

Rep. Alexandria Ocasio-Cortez (D-NY): Allows United States researchers to study and examine the potential impacts of several schedule I drugs, such as MDMA, psilocybin, and or ibogaine, that have been shown to be effective in treating critical diseases.

Rep. Kurt Schrader (D-OR): Increases and decreases by $5 million, funding for the Center for Food Safety and Applied Nutrition at the FDA, to highlight the need for the Agency to proceed with rulemaking on cannabidiol (or CBD) by no later than 180 days after enactment, out of concern that the FDA has not initiated rulemaking to establish a regulatory pathway for CBD as a dietary supplement and food ingredient.

Rep. Debbie Lesko (R-AZ): Strikes language that allows federal funding to go to institutions of higher education that are conducting research on marijuana.

Rep. Doug LaMalfa (R-CA): Transfers $25 million from the Environmental Programs and Management enforcement activities account to the National Forest System account for enforcement and remediation of illegal marijuana trespass grow sites on federal lands and for the clean-up of toxic waste and chemicals at these sites.

Here are the amendments that were not ruled in order and are thus dead: 

Rep. Eleanor Holmes Norton (D-DC): Prohibits HUD from enforcing the prohibition on the use or possession of marijuana in federally assisted housing in states where marijuana is legal.

Rep. Eleanor Holmes Norton (D-DC): Prohibits HUD from enforcing the prohibition on the use or possession of medical marijuana in federally assisted housing in states where medical marijuana is legal.

Rep. Doug LaMalfa (R-CA): Prohibits funds from this section from being used to fund needle distribution programs for illegal drugs.

Rep. Ted Butt (R-NC): Prohibits federal funds from being used to purchase clean syringes for illegal drug use.

Rep. Ted Butt (R-NC): Prohibits federal funds from being used to purchase clean syringes for illegal drug use in DC.

Rep. French Hill (R-AR): Increases funding by $50 million for the Office of National Drug Control Policy’s High Intensity Drug Trafficking Areas Program. Offsets the increase with a decrease in funding of $50 million for the Electric Vehicles Fund.


Marijuana Moment is already tracking more than 1,100 cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.

Overall, these amendments were targeted for inclusion in an appropriations “minibus” bill for fiscal year 2022 to fund the Departments of Labor, Health and Human Services, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development.

The spending package that is now heading to the House floor for votes on Tuesday also, under its language as originally introduced in appropriations subcommittees, would allow Washington, D.C. to use its local tax dollars to implement a system of lawful marijuana sales for adults.

That stands in contrast to a budget proposal from President Joe Biden, whose administration is seeking to keep language protecting medical cannabis states from federal intervention but has excluded the provision on giving D.C. autonomy to legalize marijuana commerce.

Another provision that was added as part of the Financial Services and General Government (FSGG) spending bill would protect banks that work with marijuana businesses. Further, the committee report attached to that legislation encourages federal government agencies to reconsider policies that fire employees for using marijuana in compliance with state law.

Federal health agencies should pursue research into the therapeutic potential of psychedelics for military veterans suffering from a host of mental health conditions, a report attached to separate spending legislation that’s part of the advancing minibus package says.

Report language also directs the U.S. Department of Veterans Affairs (VA) to improve communication on veteran eligibility for home loans and report back to Congress on its progress within 180 days of the enactment of the legislation. A separate provision urges VA to expand research on the medical benefits of cannabis for veterans.

In the report for Agriculture Department funding, lawmakers took issue with the 2018 Farm Bill’s 0.3 percent THC cap for lawful hemp products and directed USDA to work with the U.S. Department of Health and Human Services (HHS) and DEA on a study of whether that threshold is scientifically backed. That report also addressed numerous other issues related to the crop.

Other report language attached to this spending package highlights the difficulty of studying Schedule I drugs like marijuana, recognizes the medical potential of cannabinoids like CBD, encourages federal agencies not to restrict the plant kratom and acknowledges the lifesaving value of syringe access programs and safe consumption sites for illegal drugs.

The appropriations process this session has seen numerous drug policy reform provisions included in bill text and attached reports—also stopping immigrants from being deported for cannabis, for example, among other issues.

A bipartisan group of congressional lawmakers recently circulated a letter to build support for an amendment to a separate Department of Justice spending bill that would protect all state and tribal marijuana programs from federal interference—going beyond the existing measure that shields only medical cannabis states that’s currently enacted into law. There are now 15 cosponsors signed on to the broader proposal, which is expected to be considered by the Rules Committee and then potentially see floor action this week.

The Commerce, Justice, Science, and Related Agencies (CJS) spending report also notes that the Drug Enforcement Administration (DEA) has moved to approve additional marijuana manufacturers for research purposes and says the committee supports ongoing research efforts on cannabis, particularly in the wake of an outbreak of lung injuries associated with unregulated vaping products.

A provision was also attached to the bill that would make states and localities ineligible for certain federal law enforcement grants if they maintain a policy allowing for no-knock warrants for drug-related cases. That policy garnered national attention following the police killing of Breonna Taylor, who was fatally shot by law enforcement during a botched drug raid.

The Rules Committee is set to take up CJS and other appropriations legislation on Tuesday.

White House Declines To Blame Marijuana Sales For Violent Crime Spike Despite D.C. Police Chief’s Comments

Photo courtesy of Mike Latimer.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

White House Declines To Blame Marijuana Sales For Violent Crime Spike Despite D.C. Police Chief’s Comments

Published

on

The White House on Monday declined the chance to blame illicit marijuana sales for a rise in violent crime in Washington, D.C.—despite the city’s police chief recently arguing that the issues are connected.

D.C. Police Chief Robert Contee suggested on Friday that part of the reason for the uptick in violent crime is connected to the illegal cannabis market, which he says has been deprioritized amid the national reform movement.

“When you have something where people get high reward—they can make a lot of money by selling illegal marijuana—and the risk is low, the risk for accountability is very low, that creates a very, very, very, very, very bad situation,” Contee argued at a press conference near the site of a shooting this month.

Advocates assert that Congress bears some blame for consistently passing a spending bill rider that bars the District from regulating retail sales after voters approved a 2014 initiative to legalize personal possession and cultivation for adults, thus relegating cannabis commerce to the illegal market.

Late last month, a House committee approved a large-scale funding bill that would allow the District to legalize cannabis sales by deleting the rider. The legislation is expected to pass the full House this week.

In any case, White House Press Secretary Jen Psaki was asked directly on Monday by a Fox News reporter whether the Biden administration thinks “that it may be time to get tougher on marijuana” in light of the chief’s comments. And she notably did not jump at the chance to vilify cannabis despite President Joe Biden’s ongoing opposition to adult-use legalization.

“We look to the crime that has been happening in D.C.—again one of the cities where we’ve seen rising violence over the past year and a half,” she said, pivoting quickly away from the cannabis query to discuss crime more generally. It’s “one we’re working in close partnership through both the [Justice Department] as well as our community violence intervention collaborative. We’re looking to address a range of causes, working in close partnership with the mayor and local police to bring crime down in our city.”

The fact that Psaki decided not to take aim at marijuana specifically, despite being prompted by comments made by one of the the top law enforcement official in the nation’s capital, is significant—if only because the administration to this point has been firmly footed in maintaining the status quo of prohibition.

Biden’s budget proposal specifically proposes continuing the longstanding Republican-led rider that has prevented the city from spending its own money to regulate adult-use cannabis commerce, for example.

Rep. Eleanor Holmes Norton (D-DC) in May blasted the president in an interview with Marijuana Moment for seeking to extend the provision blocking her city from making its own cannabis decisions, saying she is “going to be working very hard to make sure that that rider is not in the budget” that lawmakers ultimately send back to Biden’s desk.

Mayor Muriel Bowser (D) said in April that local officials are prepared to move forward with implementing a legal system of recreational cannabis sales in the nation’s capital just as soon as they can get over the final “hurdle” of congressional interference.

From advocates’ perspective, allowing D.C. to do what a growing number of states have already done by regulating cannabis could help mitigate the risks associated with enabling an illicit market to continue. Giving adults the option to purchase marijuana from a licensed retailer would make it less likely that the city would see any violent criminal activity that can be tied to illegal cannabis sales, they say.

Psaki didn’t make that point, but she didn’t seize the opportunity to target cannabis as a contributing factor to D.C. violence either.

This adds to the White House narrative on marijuana that’s evolved throughout the Biden administration.

During his presidential campaign last year, Biden ran on a pledge to enact other modest reforms such as decriminalizing cannabis possession, expunging prior records and respecting the rights of states to set their own laws. Since taking office, however, his administration has not made progress on any of those promises and has instead fired its own White House staffers over marijuana and is seeking to extend the D.C. sales block.

Biden took some by surprise by suggesting that international sports rules on marijuana may need to be reevaluated after star U.S. runner Sha’Carri Richardson was suspended following a positive cannabis test. But that’s a far cry from endorsing comprehensive reform.

Psaki, for her part, initially declined to condemn Olympics officials’ sanction on Richardson when asked about the issue at an earlier briefing with reporters. But she later told CNN that the case highlights the need to “take another look” at the rules on cannabis.

In April, the press secretary said that Biden’s campaign pledge to release federal inmates with marijuana convictions will start with modestly rescheduling cannabis—a proposal that advocates say wouldn’t actually accomplish what she’s suggesting.

On broad legalization, Psaki said recently that the president remains opposed to the reform, despite Senate leadership introducing a bill this month to federally legalize marijuana.

Sen. Cory Booker (D-NJ), one of the three leaders on the measure, said recently that he and his Senate colleagues will be talking to the White House now that they’ve released draft reform legislation.

FDA Seeks Public Input On Possible Global Kratom Ban After Domestic Scheduling Effort Stalled

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading

Politics

FDA Seeks Public Input On Possible Global Kratom Ban After Domestic Scheduling Effort Stalled

Published

on

After failing to get kratom prohibited domestically, the Food and Drug Administration (FDA) is now seeking public comment to inform the U.S. position on how the substance should be scheduled under international statute.

In a notice published in the Federal Register last week, the agency is soliciting feedback on a number of substances. But advocates are especially concerned about where FDA and global drug officials come down on kratom, which has been touted as a natural painkiller that works as a safer alternative to prescription opioids.

The U.S. agency doesn’t quite see it that way, however.

“Kratom is abused for its ability to produce opioid-like effects,” FDA wrote in the notice. “Kratom is available in several different forms to include dried/crushed leaves, powder, capsules, tablets, liquids, and gum/ resin. Kratom is an increasingly popular drug of abuse and readily available on the recreational drug market in the United States.”

Responses to the notice will help inform the federal government’s stance on kratom scheduling in advance of an October meeting of the World Health Organization’s (WHO) Expert Committee on Drug Dependence, where international officials will discuss whether to recommend the substance be globally scheduled.

“The FDA’s request for public comments on a matter of such importance involving the international scheduling of kratom is an extraordinary abuse of their authority,” Mac Haddow, senior fellow of public policy at the American Kratom Association (AKA), told Marijuana Moment.

He said the August 9 deadline for the responses allows “only three weeks for scientists, public policy makers and consumers to provide responses that are well researched and responsive to the complex requirements for data and information that will be considered by the WHO Expert Committee” and is therefore “unacceptable.”

As it stands, kratom is not scheduled under the federal Controlled Substances Act or under international drug treaties to which the U.S. is a party. But some advocates suspect that since FDA has been unable so far to impose a ban on kratom domestically, it may use the WHO convention as an opportunity to get prohibition enacted internationally, a move that the country would be compelled to comply with.

“If that happens, there are 37 countries that are part of that international treaty that will effectively ban kratom around the world,” Haddow said in a recent video update to supporters. “The FDA cannot get kratom scheduled here in the United States using the criteria that’s established by the Controlled Substances Act, so they’re circumventing that and going to the WHO.”

Haddow encouraged people to take advantage of the public comment period—but to remember that WHO is the target audience for those comment, not FDA.

“We want thousands of people to comment because every one of those comments will have to be packaged up and sent to the World Health Organization,” he said. “We don’t want people complaining about the FDA overreach because we can fight that battle on a separate battleground, but we want the WHO to know the powerful experiences that people have had” with kratom.

FDA, in its Federal Register notice, said the comments “will be considered in preparing a response from the United States to the World Health Organization (WHO) regarding the abuse liability and diversion of these drugs.”

Haddow told Marijuana Moment that the federal agency “is prosecuting a war on kratom to criminalize more than 15 million Americans, and they ignore the public health impacts of kratom consumers being forced to opioids with a high potential for addiction and that can be deadly.”

“More overdose deaths will occur if kratom is banned, and that is exactly what the FDA is trying to do,” he said.

On the domestic level, the House Appropriations Committee recently approved a report to spending legislation that says federal health agencies have “contributed to the continued understanding of the health impacts of kratom, including its constituent compounds, mitragynine and 7-hydroxymitragynine.”

“The Committee is aware of the potential promising results of kratom for acute and chronic pain patients who seek safer alternatives to sometimes dangerously addictive and potentially deadly prescription opioids and of research investigating the use of kratom’s constituent compounds for opioid use disorder,” it said.

It also directed the Health and Human Services secretary to continue to refrain from recommending that kratom be controlled in Schedule I.

Late last year, the Agency for Healthcare Research and Quality (AHRQ) asked the public to help identify research that specifically looks at the risks and benefits of cannabinoids and kratom.

The Centers for Disease Control and Prevention (CDC) last year separately received more than one thousand comments concerning kratom as part of another public solicitation.

FDA has on several occasions solicited public input to shape the government’s position on the international scheduling of marijuana and cannabinoids. The agency initially requested feedback on the proposal in March 2019 and then reopened that comment period five months later.

Last year, the United Nations approved a U.S.-backed WHO recommendation to remove marijuana from the most restrictive global scheduling category. However, the U.S. opposed several other cannabis reform proposals, including the one to clarify that CBD is not under international control.

D.C. Police Chief Says Illicit Marijuana Sales Tied To Violence As Congress Weighs Lifting Regulatory Blockade

Photo courtesy of Wikimedia/ThorPorre.

Marijuana Moment is made possible with support from readers. If you rely on our cannabis advocacy journalism to stay informed, please consider a monthly Patreon pledge.
Continue Reading
Advertisement

Marijuana News In Your Inbox

Support Marijuana Moment

Marijuana News In Your Inbox

Marijuana Moment